Cargando…

Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer

Data from over 20 years ago demonstrated potential use for insulin-like growth factor (IGF) signaling modulators, specifically with IGF-1R antagonists, in a variety of pediatric and adolescent cancers, particularly in sarcomas. However, in spite of promising preclinical data, IGF-1R inhibitors have...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Michael J., Maki, Robert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563098/
https://www.ncbi.nlm.nih.gov/pubmed/23383402
http://dx.doi.org/10.3389/fonc.2013.00009
_version_ 1782258147659874304
author Wagner, Michael J.
Maki, Robert G.
author_facet Wagner, Michael J.
Maki, Robert G.
author_sort Wagner, Michael J.
collection PubMed
description Data from over 20 years ago demonstrated potential use for insulin-like growth factor (IGF) signaling modulators, specifically with IGF-1R antagonists, in a variety of pediatric and adolescent cancers, particularly in sarcomas. However, in spite of promising preclinical data, IGF-1R inhibitors have not had the success as single agents that was originally hoped for in clinical trials. Several potential mechanisms exist by which tumors are resistant to IGF-1R inhibitors. Notably, these resistance mechanisms are currently best understood in Ewing sarcoma and alveolar rhabdomyosarcoma. Various treatment schema have been proposed as a potential way to overcome this resistance. The use of IGF-1R inhibitors, mechanisms of resistance, and current ongoing clinical studies using IGF-1R inhibitors in pediatric cancers are reviewed here.
format Online
Article
Text
id pubmed-3563098
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-35630982013-02-04 Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer Wagner, Michael J. Maki, Robert G. Front Oncol Oncology Data from over 20 years ago demonstrated potential use for insulin-like growth factor (IGF) signaling modulators, specifically with IGF-1R antagonists, in a variety of pediatric and adolescent cancers, particularly in sarcomas. However, in spite of promising preclinical data, IGF-1R inhibitors have not had the success as single agents that was originally hoped for in clinical trials. Several potential mechanisms exist by which tumors are resistant to IGF-1R inhibitors. Notably, these resistance mechanisms are currently best understood in Ewing sarcoma and alveolar rhabdomyosarcoma. Various treatment schema have been proposed as a potential way to overcome this resistance. The use of IGF-1R inhibitors, mechanisms of resistance, and current ongoing clinical studies using IGF-1R inhibitors in pediatric cancers are reviewed here. Frontiers Media S.A. 2013-02-04 /pmc/articles/PMC3563098/ /pubmed/23383402 http://dx.doi.org/10.3389/fonc.2013.00009 Text en Copyright © Wagner and Maki. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Oncology
Wagner, Michael J.
Maki, Robert G.
Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer
title Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer
title_full Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer
title_fullStr Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer
title_full_unstemmed Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer
title_short Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer
title_sort type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563098/
https://www.ncbi.nlm.nih.gov/pubmed/23383402
http://dx.doi.org/10.3389/fonc.2013.00009
work_keys_str_mv AT wagnermichaelj type1insulinlikegrowthfactorreceptortargetedtherapiesinpediatriccancer
AT makirobertg type1insulinlikegrowthfactorreceptortargetedtherapiesinpediatriccancer